AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33855205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple autoantibodies (n = 46)
Number of subjects: 76
Study 33855675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant p.C182* IKAROS protein
Number of subjects: 1
Study 33855675 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up observations
Number of subjects: 1
Study 33855751 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomes carrying siRNA targeting STAT3
Number of subjects: 0
Study 33855751 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomes carrying antisense oligonucleotide (ASO) targeting STAT3
Number of subjects: 0
Study 33855885 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CGM Algorithm
Number of subjects: 0
Study 33855885 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited field launch of Modified CGM Algorithm
Number of subjects: 0
Study 33855888 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time Continuous Glucose Monitoring
Number of subjects: 0
Study 33856003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (high-dose repletion therapy) for eight weeks
Number of subjects: 11
Study 33856137 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (DW MRI)
Number of subjects: 1148
Study 33856137 — intervention group
Group type: COMPARATOR
Intervention: Combined mammography and ultrasound (US)
Number of subjects: 1148
Study 33856277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg and escalating doses of lenalidomide on Days 1-7 with DA-EPOCH-R (Days 1-5) in 21-day cycles
Number of subjects: 0
Study 33856360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted mobile NAS caregiving tool
Number of subjects: 30
Study 33856360 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 33856599 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-BCT-100 at 2.7 mg/kg weekly intravenous
Number of subjects: 27
Study 33857185 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sedation using volatile agents (Sevoflurane and Isoflurane) with the Anaesthetic Conserving Device (AnaConDa, Sedana Medical)
Number of subjects: 187
Study 33857185 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sedation
Number of subjects: 187
Study 33857326 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytics plus heparin
Number of subjects: 2401
Study 33857451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 methylated DNA marker (MDM) panel
Number of subjects: 199
Study 33857451 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 methylated DNA marker (MDM) panel
Number of subjects: 199
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired infections (HAIs)
Number of subjects: 774
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 774
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodstream infections (BSIs)
Number of subjects: 774
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-related BSIs
Number of subjects: 774
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIs complicated by septic shock
Number of subjects: 774
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation duration
Number of subjects: 774
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stay duration
Number of subjects: 774
Study 33857475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay duration
Number of subjects: 774
Study 33857524 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized fractional anisotropy (GFA) values of white matter (WM) tracts in children with ADHD
Number of subjects: 77
Study 33857524 — intervention group
Group type: COMPARATOR
Intervention: Generalized fractional anisotropy (GFA) values of white matter (WM) tracts in typically developing controls (TDC)
Number of subjects: 77
Study 33857524 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD symptom severity and diagnosis
Number of subjects: 77
Study 33857524 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-scale intellectual quotient (FIQ)
Number of subjects: 77
Study 33857679 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 9vHPV vaccine (day 1 and month 12, 24, 36, or 60) in Cohorts 1-4
Number of subjects: 700
Study 33857679 — intervention group
Group type: EXPERIMENTAL
Intervention: One study dose of 9vHPV vaccine at day 1 in Cohort 0
Number of subjects: 700
Study 33857679 — intervention group
Group type: COMPARATOR
Intervention: Three doses of 9vHPV vaccine (day 1, months 2 and 6) in Cohort 5
Number of subjects: 700
Study 33857679 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection-site and systemic adverse events (AEs)
Number of subjects: 700
Study 33857679 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events (AEs)
Number of subjects: 700
Study 33857679 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-related serious AEs and deaths
Number of subjects: 700
Study 33857731 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMIES (frequency-selective hearing protection device) worn for two consecutive 30-min periods in Phase 1
Number of subjects: 50
Study 33857731 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMIES worn between care and feeding times during an 8-h Device-On period followed by an 8-h Device-Off period for three consecutive days in Phase 2
Number of subjects: 50
Study 33857731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse evaluation of DREAMIES
Number of subjects: 50
Study 33857917 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CBT
Number of subjects: 146
Study 33857917 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 146
Study 33857917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of e-CBT and medication
Number of subjects: 146
Study 33858040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib combined with multi-agent chemotherapy regimen
Number of subjects: 0
Study 33858040 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33858202 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (adjuvant or neoadjuvant)
Number of subjects: 0
Study 33858278 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 0
Study 33858278 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 33858326 — intervention group
Group type: EXPERIMENTAL
Intervention: SDC2 methylation test using EarlyTect™-Colon Cancer test
Number of subjects: 0
Study 33858326 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33858336 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 33858336 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 0
Study 33858486 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 0
Study 33858486 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges (2/day for 90 days)
Number of subjects: 0
Study 33858486 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ (400 mg) and AMX (500 mg TID for 14 days)
Number of subjects: 0
Study 33858486 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges and MTZ+AMX
Number of subjects: 0
Study 33858803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rurality (caregivers from rural areas)
Number of subjects: 414
Study 33858803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rurality among caregivers with education ≤ high school
Number of subjects: 414
Study 33859147 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited partner treatment (EPT)
Number of subjects: 63
Study 33859147 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner HIV self-testing (HIVST)
Number of subjects: 63
Study 33859572 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term resistance-training program
Number of subjects: 0
Study 33859572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 33859620 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 33
Study 33859620 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 33
Study 33859707 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group, transcutaneous EA on Bai-hui (GV20), Nei-guan (PC6), Tian-shu (ST25), and Zu-san-li (ST36) once a day in the afternoon.
Number of subjects: 385
Study 33859707 — intervention group
Group type: COMPARATOR
Intervention: Sham EA (control group).
Number of subjects: 385
Study 33859944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygenation plus Hypofractionated Stereotactic Radiotherapy (HBO-RT)
Number of subjects: 9
Study 33860280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative infusion of [U-13C] glucose
Number of subjects: 22
Study 33860387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosigna test
Number of subjects: 809
Study 33860387 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 809
Study 33860406 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired intraoperative cerebrovascular autoregulation (CVA)
Number of subjects: 195
Study 33860406 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy
Number of subjects: 195
Study 33860406 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with midazolam
Number of subjects: 195
Study 33860531 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (specifically Venlafaxine)
Number of subjects: 626
Study 33860531 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 626
Study 33860531 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 626
Study 33860531 — intervention group
Group type: COMPARATOR
Intervention: NRSIs
Number of subjects: 626
Study 33860864 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive radiofrequency (BTL-6000 TR-Therapy Pro®) applied for 10 min with epidermal temperature above 40°C
Number of subjects: 5
Study 33860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole treatment for 8 weeks
Number of subjects: 96
Study 33860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole treatment
Number of subjects: 96
Study 33860951 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month abstinent
Number of subjects: 4030
Study 33860951 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorder (AUD)
Number of subjects: 4030
Study 33860951 — intervention group
Group type: COMPARATOR
Intervention: Low-risk drinkers
Number of subjects: 4030
Study 33861204 — intervention group
Group type: EXPERIMENTAL
Intervention: Movn mobile app, supportive push-through messages (3 times per week), and Charge 2 (Fitbit Inc) activity tracker
Number of subjects: 60
Study 33861204 — intervention group
Group type: COMPARATOR
Intervention: Usual care with pedometer and daily steps recorded in a diary
Number of subjects: 60
Study 33861209 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record-embedded individualized pain plans
Number of subjects: 160
Study 33861210 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC intervention (Sex Workers Promoting Action, Risk Reduction, and Community Mobilization) drop-in center and mobile outreach program; services include harm reduction, reproductive health, sexual health care, medication-assisted treatment, legal aid, counseling, and distribution of harm reduction tools.
Number of subjects: 385
Study 33861210 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants from areas of Baltimore not predefined as closest to SPARC).
Number of subjects: 385
Study 33861212 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol and stigma coping
Number of subjects: 500
Study 33861212 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol
Number of subjects: 500
Study 33861212 — intervention group
Group type: COMPARATOR
Intervention: Control topics only
Number of subjects: 500
Study 33861303 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 167
Study 33861486 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 2.0 mg daily
Number of subjects: 9
Study 33861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status Scale score
Number of subjects: 73
Study 33861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps muscle size
Number of subjects: 73
Study 33861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility function scores
Number of subjects: 73
Study 33861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health-related quality of life
Number of subjects: 73
Study 33861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Child physical health-related quality of life at hospital discharge
Number of subjects: 73
Study 33862302 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 10
Study 33862302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 10
Study 33862302 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 10
Study 33862302 — intervention group
Group type: COMPARATOR
Intervention: Unchanged regimens (Control)
Number of subjects: 10
Study 33863399 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom virtual reality simulator training for ophthalmologic surgical procedures
Number of subjects: 0
Study 33863399 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom virtual reality simulator training for PDS implantation
Number of subjects: 0
Study 33863399 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom virtual reality simulator training
Number of subjects: 0
Study 33863661 — intervention group
Group type: EXPERIMENTAL
Intervention: Magmaris implantation with high endothelial shear stress (ESS)
Number of subjects: 22
Study 33863661 — intervention group
Group type: EXPERIMENTAL
Intervention: Magmaris implantation with low ESS
Number of subjects: 22
Study 33863661 — intervention group
Group type: EXPERIMENTAL
Intervention: Magmaris implantation with intermediate ESS
Number of subjects: 22
Study 33863713 — intervention group
Group type: COMPARATOR
Intervention: Synthetic data
Number of subjects: 1543
Study 33863713 — intervention group
Group type: COMPARATOR
Intervention: Real data
Number of subjects: 1543
Study 33863774 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) parameters including time, frequency, and non-linear domains; gender and temperature.
Number of subjects: 203
Study 33863774 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV parameters and blood biomarkers (absolute neutrophil count and C reactive protein).
Number of subjects: 203
Study 33863803 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measured by hyperinsulinemic euglycemic clamp
Number of subjects: 23
Study 33863803 — intervention group
Group type: COMPARATOR
Intervention: Post-bariatric surgery
Number of subjects: 23
Study 33863803 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin response in women who lost weight
Number of subjects: 23
Study 33863808 — intervention group
Group type: COMPARATOR
Intervention: Standard RANO
Number of subjects: 47
Study 33863808 — intervention group
Group type: EXPERIMENTAL
Intervention: iRANO
Number of subjects: 47
Study 33863808 — intervention group
Group type: EXPERIMENTAL
Intervention: mRANO
Number of subjects: 47
Study 33863856 — intervention group
Group type: EXPERIMENTAL
Intervention: Olorinab (3 or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 1 day before colitis induction
Number of subjects: 0
Study 33863856 — intervention group
Group type: EXPERIMENTAL
Intervention: Olorinab (1, 3, 10, or 30 mg/kg) administered twice daily by oral gavage for 5 days starting 24 days after colitis induction
Number of subjects: 0
Study 33863856 — intervention group
Group type: COMPARATOR
Intervention: Control animals (vehicle)
Number of subjects: 0
Study 33863913 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant
Number of subjects: 31
Study 33864173 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary cemented rotating platform device
Number of subjects: 200
Study 33864229 — intervention group
Group type: EXPERIMENTAL
Intervention: Gocovri (amantadine) 274 mg daily at bedtime
Number of subjects: 196
Study 33864229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 33864240 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily injectable recombinant human growth hormone (GH) formulations (e.g. Norditropin)
Number of subjects: 0
Study 33864240 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33864948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis (patients with cirrhosis)
Number of subjects: 96
Study 33864948 — intervention group
Group type: COMPARATOR
Intervention: No cirrhosis (patients without cirrhosis)
Number of subjects: 96
Study 33864948 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIF-C score
Number of subjects: 96
Study 33864948 — intervention group
Group type: EXPERIMENTAL
Intervention: NACSELD score
Number of subjects: 96
Study 33864948 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP score
Number of subjects: 96
Study 33864948 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD-Na score
Number of subjects: 96
Study 33865150 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoactive substances for stress management
Number of subjects: 46203
Study 33865150 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoactive substances for sleep management
Number of subjects: 46203
Study 33865150 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical use (NMU) of drugs
Number of subjects: 46203
Study 33865150 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulant medications
Number of subjects: 46203
Study 33865150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement (NE)
Number of subjects: 46203
Study 33865150 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms and social media influence
Number of subjects: 46203
Study 33865203 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK inhibitor (MEKi)
Number of subjects: 62
Study 33865400 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 32
Study 33865400 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 32
Study 33865434 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimingjia adjunct therapy with desloratadine dry suspension
Number of subjects: 206
Study 33865434 — intervention group
Group type: COMPARATOR
Intervention: Placebo with desloratadine dry suspension
Number of subjects: 206
Study 33865450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) program for six months
Number of subjects: 39
Study 33865456 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) of the dorsomedial prefrontal cortex, 20-30 sessions over 6 weeks
Number of subjects: 19
Study 33865456 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 19
Study 33865555 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cortical thickness
Number of subjects: 86
Study 33865555 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative EEG delta power
Number of subjects: 86
Study 33865555 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between mean cortical thickness and delirium status
Number of subjects: 86
Study 33865615 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 57
Study 33865734 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 7097
Study 33865770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) examination
Number of subjects: 156
Study 33865770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher native T1
Number of subjects: 156
Study 33865770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher native T2
Number of subjects: 156
Study 33865770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher left ventricular (LV) mass index
Number of subjects: 156
Study 33865778 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 148
Study 33865778 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR imaging
Number of subjects: 148
Study 33865788 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE group (n=72)
Number of subjects: 104
Study 33865788 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE within 7 days
Number of subjects: 104
Study 33865788 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE prevalence
Number of subjects: 104
Study 33865788 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up CMRI
Number of subjects: 104
Study 33865788 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial fibrosis detected on CMR
Number of subjects: 104
Study 33865810 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-based software algorithm for detecting AF
Number of subjects: 455699
Study 33866464 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in cerebrospinal fluid (CSF) before and during delayed cerebral ischemia (DCI)
Number of subjects: 263
Study 33866464 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 263
Study 33866464 — intervention group
Group type: EXPERIMENTAL
Intervention: Early leptin concentration in serum
Number of subjects: 263
Study 33866464 — intervention group
Group type: EXPERIMENTAL
Intervention: Early leptin concentration in CSF
Number of subjects: 263
Study 33866464 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcome after 12 months (extended Glasgow outcome scale)
Number of subjects: 263
Study 33866531 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral sodium selenite (dosing regimens: 33 mg daily, 11 mg BID, 5.5 mg TID)
Number of subjects: 15
Study 33866662 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication history interview conducted by pharmacists
Number of subjects: 14511